News

Premia Partners Launches Innovative ETF on HKEX for Investors

Premia Partners Launches Innovative ETF on HKEX for Investors

Premia Partners Launches a New ETF on HKEX

Premia Partners has made an exciting move in the ETF landscape with the introduction of the Premia J.P. Morgan Asia Credit Investment Grade USD Bond ETF on the Hong Kong Exchanges and Clearing Limited (HKEX). This new ETF offers investors a chance to tap into a well-diversified selection of investment-grade USD bonds from various sectors across Asian markets, while excluding Japan. With this initiative, Premia further cements its role as a trusted local ETF provider.

Exploring the ETF's Structure and Advantages

This ETF features a physically replicated structure that includes a wide range of USD bonds sourced from sovereign, quasi-sovereign, and corporate issuers throughout Asia. It boasts a competitive total expense ratio of just 0.23% per annum, showcasing its commitment to keeping costs low for investors. In today's investment climate, managing expenses effectively can significantly boost overall returns.

Focus on Investment Grade Bonds

The ETF concentrates exclusively on securities rated as investment grade by leading credit agencies like S&P, Moody's, and Fitch, providing an added layer of safety and reliability. Importantly, it shuns high-risk instruments, such as Additional Tier 1 bonds and Contingent Convertibles, which helps to protect investors' capital while still seeking potential yields.

Trading and Accessibility Features

Investors can trade this ETF during the Asia time zone, aligning with the trading hours of the underlying assets. This synchronization enhances liquidity and pricing accuracy. Additionally, the ETF benefits from exemptions on certain transaction fees, including Hong Kong stamp duties as well as the trading and settlement fees specified by HKEX.

Diversifying Investment Portfolios

This new investment vehicle is designed for those looking to boost the diversification of their portfolios. With just a single ticker, investors can access a variety of high-quality bonds, simplifying the investment process. The ETF supports strategies for portfolio completion, income stabilization, and effective asset allocation.

Insights from Leadership

Rebecca Chua, Managing Partner at Premia Partners, shared her excitement about the new offering, remarking, "We are thrilled to introduce our new ETF, which targets investors looking for exposure to Asia ex-Japan USD investment grade bonds. This product is not only timely but also crafted for cost-effective allocation and strategic navigation of the current interest rate environment."

About Premia Partners

Since its founding in 2016, Premia Partners has established itself as one of Hong Kong's leading ETF managers. The company is dedicated to creating a suite of low-cost, efficient investment vehicles to meet the needs of Asian investors. The launch of this ETF marks an important expansion of their existing fixed income suite, which now features ten ETF offerings across both equity and fixed income markets, enhancing investment strategies throughout Asia.

Contact Information

If you have questions about the new ETF or need further information about Premia Partners, feel free to reach out through the following:
Phone: +852 2950 5777
Email: enquiries@premia-partners.com

Frequently Asked Questions

What is the Premia J.P. Morgan Asia Credit Investment Grade USD Bond ETF?

This ETF allows investors to access a diversified collection of investment-grade USD bonds derived from sovereign, quasi-sovereign, and corporate issuers across Asia, excluding Japan.

What investment strategies does the ETF employ?

The ETF emphasizes investment-grade debts and uses market value-weighted techniques while steering clear of high-risk instruments, thereby ensuring safer investments.

What cost advantages does the ETF offer investors?

With a total expense ratio of 0.23% per annum, the ETF helps lower costs for investors, ultimately improving potential returns.

Why should investors trade this ETF on HKEX?

Trading on HKEX enables investors to align their transactions with the local timezone, taking advantage of reduced transaction costs due to waivers on certain fees.

What is the mission of Premia Partners?

Premia Partners focuses on creating efficient, low-cost ETFs catering to Asian investors, providing them with tools for complete asset allocation and diversification.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading